Хайлтын үр дүнгүүд - Takeshi Isoyama

  • 5-н 1 - 5 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Intracellular Redistribution of Truncated La Protein Produced by Poliovirus 3C <sup>pro</sup> -Mediated Cleavage

    Intracellular Redistribution of Truncated La Protein Produced by Poliovirus 3C <sup>pro</sup> -Mediated Cleavage -н Kazuko Shiroki, Takeshi Isoyama, Shusuke Kuge, Toshihiko Ishii, Shinobu Ohmi, Syoji Hata, Koichi Suzuki, Yoshinari Takasaki, Akio Nomoto

    Хэвлэсэн 1999
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model

    DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model -н Takeshi Jimbo, Mana Hatanaka, Takahiro Komatsu, Tomoe Taira, Kentaro Kumazawa, Naoyuki Maeda, Takashi Suzuki, Masahiro Ota, Noriyasu Haginoya, Takeshi Isoyama, Kôsaku Fujiwara

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    <scp>NTRK3</scp> kinase fusions in Spitz tumours

    <scp>NTRK3</scp> kinase fusions in Spitz tumours -н Iwei Yeh, Meng Kian Tee, Thomas Botton, A. Hunter Shain, Alyssa J. Sparatta, Alexander Gagnon, Swapna S. Vemula, María C. Garrido, Kenji Nakamaru, Takeshi Isoyama, Timothy H. McCalmont, Philip E. LeBoit, Boris C. Bastian

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

    The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models -н Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh‐hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

    U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors -н Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Sun, Heather A. Wakelee, Russell W. Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai‐Hong Ignatius Ou

    Хэвлэсэн 2020
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: